目的 比较痰热清注射液和血必净注射液治疗慢性阻塞性肺疾病急性加重期（AECOPD）的临床疗效。方法 选取2013年10月-2015年5月在黄石市中心医院呼吸科治疗的AECOPD患者150例，随机分为对照组、痰热清组和血必净组，每组各50例。对照组给予吸氧、注射用多索茶碱止咳、吸入糖皮质激素平喘、注射用头孢哌酮钠舒巴坦抗感染、纠正电解质和酸碱失衡等常规治疗。痰热清组在对照组的基础上静脉滴注痰热清注射液，20 mL加入到0.9%氯化钠注射液250 mL中，1次/d。血必净组在对照组的基础上静脉滴注血必净注射液，30 mL加入到0.9%氯化钠注射液250 mL中，1次/d。3组均治疗7 d。观察3组临床疗效，比较3组肺功能和炎性因子。结果 治疗后，对照组、血必净组和痰热清组的总有效率分别为52.0%、76.0%、82.0%，血必净组和痰热清组的总有效率均显著高于对照组，3组比较差异性具有统计学意义（P<0.05）；但痰热清组和血必净组的总有效率比较差异无统计学意义。治疗后，3组用力肺活量（FVC）、第1秒用力呼气容积（FEV1）和FEV1/FVC均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且痰热清组和血必净组这些观察指标的上升程度明显优于对照组，3组比较差异具有统计学意义（P<0.05）；但痰热清组和血必净组这些观察指标比较差异无统计学意义。治疗后，3组白细胞介素-6（IL-6）、白细胞介素-8（IL-8）、肿瘤坏死因子（TNF-α）和C-反应蛋白（CRP）均显著下降，而白细胞介素-10（IL-10）均显著上升，同组治疗前后比较差异有统计学意义（P<0.05）；且痰热清组和血必净组这些观察指标的改善程度明显优于对照组，3组比较差异具有统计学意义（P<0.05）；且血必净组这些观察指标的改善程度明显优于痰热清组，两组比较差异具有统计学意义（P<0.05）。结论 痰热清注射液和血必净注射液均能显著提高AECOPD患者的临床疗效，改善肺功能和抑制炎性因子释放，但血必净注射液抑制炎性因子释放更显著，具有一定的临床推广应用价值。

Objective To compare the clinical effect of Tanreqing Injection and Xuebijing Injection in treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Patients (150 cases) with AECOPD in Department of Respiration of Huangshi Central Hospital from October 2013 to May 2015 were randomly divided into control, Tanreqing, and Xuebijing groups, and each group had 50 cases. Patients in the control group were given the conventional treatment, including oxygen inhalation, injection administration with doxofylline for cough, inhalation administration with corticosteroids for asthma, injection administration with cefoperazone sodium and sulbactam sodium for infection, and correcting electrolyte and acid-base imbalance. Patients in the Tanreqing group were iv administered with Tanreqing Injection on the basis of the control group, 20 mL added into normal saline 250 mL, once daily. Patients in the Xuebijing group were iv administered with Xuebijing Injection on the basis imbalance. Patients in the Tanreqing group were iv administered with Tanreqing Injection on the basis of the control group, 20 mL added into normal saline 250 mL, once daily. Patients in the Xuebijing group were iv administered with Xuebijing Injection on the basis of the control group, 30 mL added into normal saline 250 mL, once daily. Patients in three groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and lung function and inflammatory factors in three groups were compared. Results After treatment, the clinical efficacies in the control, Tanreqing, and Xuebijing groups were 52.0%, 76.0%, and 82.0%, respectively, and the clinical efficacies of Tanreqing and Xuebijing groups were significantly higher than those in the control group, and there was difference among three groups (P<0.05). But there was no difference between Tanreqing and Xuebijing groups. After treatment, FVC, FEV1, and FEV1/FVC in three groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the Tanreqing and Xuebijing groups were significantly higher than those in the control group, with significant difference among three groups (P<0.05). But there was no difference between Tanreqing and Xuebijing groups. After treatment, IL-6, IL-8, TNF-α, and CRP in three groups were significantly decreased, but IL-10 in three groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the Tanreqing and Xuebijing groups were significantly better than those in the control group, with significant difference among three groups (P<0.05). And the observational indexes in the Xuebijing group were significantly better than those in the Tanreqing group, with significant difference between two groups (P<0.05). Conclusion Tanreqing Injection and xuebijing Injection both can significantly increase the clinical curative effect in treatment of AECOPD, and improve lung function, inhibit the release of inflammatory factors, but the effect of Xuebijing Injection on inhibiting the release of proinflammatory cytokines is more significant, which has a certain clinical application value.